

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 March 2002 (07.03.2002)

PCT

(10) International Publication Number
WO 02/17902 A1

- (51) International Patent Classification⁷: **A61K 31/12** (74) Agents: **DONATIELLO, Guy, T.** et al.; Schnader Harrison Segal & Lewis, LLP, 1600 Market Street - Suite 3600, Philadelphia, PA 19103 (US).
- (21) International Application Number: PCT/US01/26961
- (22) International Filing Date: 29 August 2001 (29.08.2001) (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/228,727 29 August 2000 (29.08.2000) US
- (71) Applicant (*for all designated States except US*): **TAKARA SHUZO CO. LTD** [JP/JP]; Seta 3-4-1, Otsu, Shiga 520-2193 (JP).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **INOUE, Masayori** [US/US]; Apartment 107B, 280 River Road, Piscataway, NJ 08854 (US). **PHADTARE, Sangita** [US/US]; Apartment 10A, Bartle Court, Highland Park, NJ 08904 (US). **YAMANAKA, Kunitoshi** [JP/JP]; Department of Molecular Cell Biology, Institute of Molecular Embryology & Genetics, Kumamoto University, 4-24-1 Kuhonji, Kumamoto 862-0976 (JP). **KATO, Ikunoshin** [JP/JP]; 1-1-150, Nanryo-cho, Uji-shi, Kyoto (JP).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: GENE CONFERRING RESISTANCE TO THE ANTIBACTERIAL 4,5-DIHYDROXY-2-CYCLOPENTEN-1-ONE (DHCP), THE PROTEIN ENCODED BY SAME, AND APPLICATIONS THEREOF

(57) Abstract: The invention relates to a gene, *dep*, which confers resistance to the antibacterial activity of 4,5-dihydroxy-2-cyclopenten-1-one (DHCP). The invention further relates to the putative protein encoded by *dep*, which is a hydrophobic, transmembrane efflux protein specific for DHCP. The invention further relates to plasmids containing the *dep* gene, and to bacterial cells expressing *dep*. Furthermore, the invention provides applications for use in conferring resistance to antibacterial activity in organisms. The *dep* gene can be used to identify compounds which inhibit the efflux activity responsible for the resistance to DHCP or to compounds which are functionally equivalent to DHCP.



WO 02/17902 A1

Gene conferring resistance to the antibacterial 4,5-dihydroxy-2-cyclopenten-1-one (DHCP), the protein encoded by same, and applications thereof

This patent application claims the benefit of U.S. Provisional Application No. 60/228,727, filed 8/29/2000. This earlier provisional application is hereby incorporated by reference.

In spite of a number of antibiotics available against a variety of bacteria, due to
5 emergence of multiple drug resistant strains, the search for newer and more effective
antibacterial compounds has continued. 4,5-dihydroxy-2-cyclopenten-1-one (DHCP) (see Fig.1)
is a compound having antibacterial activity against a variety of gram-positive and -negative
bacteria, such as *Escherichia coli*, *Bacillus*, *Salmonella*, *Staphylococcus* etc. The process for
manufacture and the properties of DHCP have been patented (Koyama *et al.*, 1999). It is
10 prepared by the heat-treatment of uronic acid or its derivatives, wherein uronic acid is
galacturonic acid, glucuronic acid, mannuronic acid or iduronic acid. It is also produced from
roasted or parched vegetables, fruits, cereals, mushrooms, sea algae, cortex or cartilage. It has
been demonstrated that this compound induces cancer cell differentiation and apoptosis. It has
potential application as therapeutic or preventive agent against cancer and also as an antibacterial
15 agent in antiseptics, dentrifices, cosmetics and bathing agents (Koyama *et al.*, 1999).

We have isolated a multicopy suppressor from an *E. coli* genomic library for the DHCP
toxicity. The putative protein encoded by this gene showed high homology to known efflux
proteins conferring resistance to a number of antibiotics including chloramphenicol,
bicyclomycin and tetracycline. The gene was mapped at 37.5 min on the *E. coli* chromosome. It
20 is designated as *dep* for DHCP efflux protein. However, the Dep protein does not confer cross-
resistance to any of the antibiotics tested.

Prior Art References

United States Patent No. 6,087,401 to Koyama, et al. Cyclopentones, process for preparing same, and the use thereof.

5

This patent discloses a method of manufacturing 4,5-dihydroxy-2-cyclopenten-1-one (DHCP). It also describes the antibacterial activity of DHCP.

10

In contrast, the invention disclosed in the present provisional application relates to a gene, *dep*, that, when present in multiple copies in bacterial cells, confers resistance to the antibacterial activity of DHCP, thus rendering the bacteria resistant to killing by DHCP. The present application also describes the protein encoded by the *dep* gene.

15

European Patent EP 0 941 981 A1 to Koyama, et al. Cyclopentones, process for preparing same, and the use thereof.

This patent application relates to essentially the same subject matter as that described in United States Patent No. 6,087,401 to Koyama, et al.

20

United States Patent No. 6,111,145 to Kobayashi et al. Cyclopentenone derivative.

This patent relates to functionally equivalent ether derivatives of DHCP and discloses the biological activity of these derivatives.

25

European Patent Publication EP 1 000 923 A1 to Kobayashi et al. Cyclopentenone derivatives.

This patent application relates to essentially the same subject matter as that described in United States Patent No. 6,111,145 to Kobayashi et al.

United States Patent No. 6,136,854 to Koyama et al. Cyclopentenone derivative.

5

This patent relates to functionally equivalent ester derivatives of DHCP and discloses the biological activity of these derivatives.

European Patent Publication EP 0 976 717 A1 to Koyama et al. Cyclopentenone derivatives.

10

This patent application relates to essentially the same subject matter as that described in United States Patent No. 6,136,854 to Koyama et al.

15

Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. C. Wuchter, et al. Haematologica 85(7):711-21 (2000).

20

In acute leukemia, a multidrug-resistance (MDR) phenotype mediated by P-glycoprotein (P-gp) contributes to chemotherapy failure. This study investigated whether P-gp expression levels or functional P-gp activity was a better predictor of response to induction chemotherapy, relapse rate and overall survival in acute leukemia. The data demonstrated that the functional rhodamine-123- (rh123)-efflux assay was preferred over P-gp expression analysis by monoclonal antibodies in acute leukemia.

25

Increased drug delivery to the brain by P-glycoprotein inhibition. A.J. Sadeque, et al. Clinical Pharmacology & Therapeutics 68(3):231-7 (2000).

In vitro studies had demonstrated that the antidiarrheal drug loperamide is a substrate for the efflux membrane transporter P-glycoprotein. Although loperamide is a potent opiate drug, it does not opiod central nervous system effects, such as respiratory depression, when given to patients at usual doses. This study tested the hypothesis that inhibition of P-glycoprotein with quinidine would increase the entry of loperamide into the central nervous system, thus causing respiratory depression. The results demonstrated that although loperamide produced no respiratory depression when used alone, respiratory depression was seen when loperamide was administered with quinidine.

Expression of the multidrug-resistance-associated protein in myelodysplastic syndromes. S. Poulain, et al. British Journal of Haematology 110(3):591-8 (2000).

In myelodysplastic syndromes (MDS), P-glycoprotein (P-gp) expression is associated with drug resistance, while the clinical significance of the multidrug resistance-associated protein (MRP1) is unclear. In this study of bone marrow from patients with MDS, expression of MRP1 was correlated with disease stage in MDS. With respect to P-gp, discordant expression/function of MRP1 was found in some cases, suggesting the existence of nonfunctional transport proteins in MDS. MRP1 expression did not appear to be a prognostic factor in MDS.

Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. B. E. Plaat, et al. Journal of Clinical Oncology 18(18):3211-20 (2000).

In this study, parameters associated with multidrug resistance (MDR) were compared between soft tissue leiomyosarcomas (LMS) and malignant gastrointestinal stromal tumors (GIST). Immunohistochemistry was used to detect P-glycoprotein (P-gp), multidrug resistance protein (MRP(1)), lung resistance protein (LRP), and c-kit. The results demonstrate that LMS

patients have better survival rates compared to GIST patients, and the pattern of metastasis differs between the two patient groups. The expression of the MDR proteins tested is less pronounced in LMS than in GIST.

- 5 Quorum sensing in *Escherichia coli*, *Salmonella typhimurium*, and *Vibrio harveyi*: A new family of genes responsible for autoinducer production. M.G. Surette, et al. Proc. Natl. Acad. Sci. 96:1639-44 (1999).

In bacteria, the regulation of gene expression in response to changes in cell density, called quorum sensing, is dependent on hormone-like molecules known as autoinducers that are produced by the bacteria and accumulate in the external environment as the bacterial cell population increases. The marine bacterium *Vibrio harveyi* has been shown to have two parallel quorum sensing systems, each composed of a sensor-autoinducer pair. The two different autoinducers belonging to each system have been termed autoinducer 1 (AI-1) and autoinducer 2 (AI-2). The identification and analysis of the genes responsible for AI-2 production in *E. coli*, *S. typhimurium*, and *V. harveyi* is reported.

Quorum sensing in *Vibrio fischeri*: Probing autoinducer-LuxR interactions with autoinducer analogs. A. L. Schaefer, et al. Journal of Bacteriology 178:2897-2901 (1996).

- 20 In *Vibrio fischeri*, luminescence genes are activated by the transcription factor LuxR in combination with a diffusible signal compound known as the autoinducer. This study analyzed the ability of a number of autoinducer analogs to interact with LuxR.

Regulation of quorum sensing in *Vibrio harveyi* by LuxO and Sigma-54. B.N. Lilley and B. L. Bassler. Molecular Microbiology 36(4):940-954 (2000).

The bioluminescent marine bacterium *Vibrio harveyi* controls light production (*lux*) by a quorum-sensing circuit. This study demonstrates that the response regulator protein LuxO functions as an activator protein via interaction with the alternative sigma factor, σ^{54} . Since LuxO is responsible for repression of the luciferase structural operon (*luxCDABEGH*), these results suggest that LuxO, together with σ^{54} , functions to activate a negative regulator of luminescence.

14. Bentley, J., Hyatt, L.S., Ainley, K., Parish, J.H., Herbert, R.B., and White, G.R. 1993. Cloning and sequence analysis of an *Escherichia coli* gene conferring bicyclomycin resistance. *Gene* 127: 117-120.
15. Berlyn, M.K.B., Low, K.B., and Rudd, K.E. 1996. Linkage map of *Escherichia coli* K-12, Ed. 9. Pages 1715-1902. In Neidhardt, F.C., Curtiss III, R., Ingraham, J.L., Lin, E.C.C., et al. (ed) *Escherichia coli and Salmonella. Cellular and Molecular Biology*, Vol. 2, 2nd Ed., ASM Press, Washington DC.
16. Desomer, J., Vereecke, D., Crespi, M., and Van Montagu, M. 1992. The plasmid-encoded chloramphenicol-resistance protein of *Rhodococcus fascians* is homologous to the transmembrane tetracycline efflux proteins. *Mol. Microbiol.* 6: 2377-2385.
17. Dittrich, W., Betzler, M., and Schrempf, H. 1991. An amplifiable and deletable chloramphenicol-resistance determinant of *Streptomyces lividans* 1326 encodes a putative transmembrane protein. *Mol. Microbiol.* 5:2789-2797.
18. Hiraga S., Niki, H., Ogura, T., Ichinose, C., Mori, H., Ezaki, B., and Jaffe, A. 1989. Chromosome partitioning in *Escherichia coli*: novel mutants producing anucleate cells. *J. Bacteriol.* 171:1496-505.
19. Koyama, N., Sagawa, H., Kobayashi, E., Enoki, T., Wu, H-K., Nishiyama, E., Ikai, K., and Kato, I. 1999. Cyclopentanones, process for preparing the same, and the use thereof. European Patent (EP 0941 981 A1, date of publication: 09/15/1999).

20. Lu Q., and Inouye, M. 1998. The gene for 16S rRNA methyltransferase (*ksgA*) functions as a multicopy suppressor for a cold-sensitive mutant of Era, an essential RAS-like GTP-binding protein in *Escherichia coli*. J. Bacteriol. 180:5243-5246.
21. Mosher, R.H., Camp, D.J., Yang, K., Brown, M.P., Shawl, W.V., and Vining, L.C. 1995. Inactivation of chloramphenicol by O-phosphorylation. J. Biol. Chem. 270:27000-27006.
22. Nagy, I., Schoofs, G., Vanderleyden, J., and De Mot, R. 1997. Transposition of the IS21-related element IS1415 in *Rhodococcus erythropolis*. J. Bacteriol. 179:4635-4638.
23. Ohki, R., and Murata, M. 1997. *bmr3*, a third multidrug transporter gene of *Bacillus subtilis*. J. Bacteriol. 179:1423-1427.
24. Rouch, D.A., Cram, D.S., DiBerardino, D., Littlejohn, T.G., and Skurray, R.A. 1990. Efflux-mediated antiseptic resistance gene *qacA* from *Staphylococcus aureus*: common ancestry with tetracycline- and sugar-transport proteins. Mol. Microbiol. 4:2051-2062.
25. Schwarz, S., Cardoso, M., and Wegener, H.C. 1992. Nucleotide sequence and phylogeny of the *tet(L)* tetracycline resistance determinant encoded by plasmid pSTE1 from *Staphylococcus hyicus*. Antimicrob. Agents Chemother. 36:580-588.
26. Yanisch-Perron, C., Vieira, J., and Messing, J. 1985. Improved M13 phage cloning vectors and host strains: Nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33: 103-119.

All references cited herein are incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is the chemical structure of 4,5-dihydroxy-2-cyclopenten-1-one (DHCP).

FIG. 2A is a graphical representation of the effect of DHCP concentration on the growth
5 of *E. coli*.

FIG. 2B is a graphical representation of the effect of DHCP concentration on the survival
of *E. coli*.

FIG. 3 is a restriction mapping of the plasmid pSP001 showing the DNA fragments
conferring resistance to DHCP.

10 FIG. 4 is a comparison of the amino acid sequence of the polypeptide encoded by *dep*
with the proteins encoded by *cmr*, *cmrA*, *cmx*, *cmlv*, *bcr*, *bmr3*, *yjcC*, and *tet*.

FIG. 5 is a comparison of the hydropathic profiles of the putative proteins encoded by
dep, *cmr*, and *cml*.

15 FIG. 6 is a nucleotide sequence showing the DNA sequence of a region of the *E. coli*
genome containing the sequence of the *dep* gene.


FIG. 7 is a nucleotide sequence showing the isolated DNA sequence of the *dep* gene.

BRIEF DESCRIPTION OF THE INVENTION


The provisional application describes the cloning of a gene encoding a transmembrane protein from *E. coli*. This protein, when expressed from a multi-copy plasmid, functions to transport 4,5-dihydroxy-2-cyclopenten-1-one (DHCP) out of the cell.

5 DHCP and functionally equivalent compounds are represented by the formulas [I] and [II] and include optically active compounds thereof. In Formula I, R^1 and R^2 are the same or different and each of them is hydrogen, a straight or branched alkyl group, a straight or branched alkenyl group, an aromatic group, an aromatic-aliphatic group, with the proviso that $R^1 =$ a benzyl group and $R^2 = H$ is excluded.

10 See References 3 and 4. R^3 - R^6 are independently hydrogen or an alkyl group, preferably a lower alkyl group such as a C_1 - C_6 alkyl.



Formula I



Formula II

In Formula II, R^1 and R^2 are the same or different and each of them is hydrogen, a straight or branched alkyl group, a straight or branched alkenyl group, an aromatic group, an aromatic-aliphatic group, with the proviso that the case where $R^1 = R^2 = \text{CH}_3$ is excluded. See References 5 and 6. R^3 - R^6 are independently hydrogen or an alkyl group, preferably a lower alkyl group such as a C_1 - C_6 alkyl.

DHCP is shown to possess anti-bacterial activity; it inhibits cell growth at a concentration of $350\mu\text{M}$ or higher. At lower concentrations, it causes cells to elongate and grow poorly. To determine if *E. coli* is naturally resistant to DHCP, a library of *E. coli* genomic DNA fragments was transformed into strain JM83 and grown on agar plates containing $400\mu\text{M}$ DHCP. Colonies that were capable of growing on this medium were isolated. DNA was isolated from these colonies to identify and sequence the cloned genomic fragment that specified resistance. Four genes were found in the fragment that conferred resistance. Inactivation of various combinations of these four genes led to the conclusion that ORF389 was responsible for conferring resistance. This was confirmed by cloning ORF389 by itself into pUC19 (a multi-copy plasmid) and transforming strain JM83. The resultant cells were resistant to DHCP.

Comparison of the nucleotide sequence of ORF389 with the *E. coli* gene database showed that it was similar to known efflux proteins involved in conferring resistance to chloramphenicol and other antibiotics. Further analysis of the predicted structure of the protein encoded by ORF389 suggested that it was a membrane protein; it possesses multiple
5 transmembrane domains and shares structural similarity with the aforementioned chloramphenicol efflux polypeptides.

To determine if ORF389 was capable of conferring resistance to other antibiotics such as chloramphenicol, spectinomycin, and tetracycline, the transformed JM83 cells containing the pUC19/ORF389 plasmid were plated on media containing these antibiotics. The presence of
10 ORF389 failed to confer resistance to any antibiotic other than DHCP, suggesting that the efflux activity of the Dep protein is specific for DHCP.

It is important to note that ORF389 confers resistance to DHCP only when it is present in multiple copies in the cell. The gene is naturally found in the genome of *E. coli* cells, but it is present in single copy. Such cells are susceptible to the antimicrobial activity of DHCP. When
15 ORF389 is cloned into pUC19 and introduced into JM83 cells, it is present in multiple copies (up to several hundred copies of the gene per cell), since pUC19 is maintained in up to several hundred copies per cell. Only when the gene dosage is increased, is resistance to DHCP found. The mechanism of resistance is simply increased efflux activity arising from the increased expression of the efflux protein in the transformed cells.

20 It should be noted that due to the degeneracy of the genetic code, the nucleotide sequence encoding an efflux protein that is responsible for conferring resistance to DHCP or a compound functionally equivalent to DHCP may vary from the nucleic acid sequence disclosed herein.

ADDITIONAL DESCRIPTION OF THE INVENTION

Mode of Action

DHCP is a compound that exhibits antimicrobial and anti-tumor activity. It is made by heating various uronic acids (e.g., glucuronic acid, galacturonic acid, mannuronic acid). The inventors have cloned a gene from *E. coli* that encodes a protein which is capable of transporting DHCP out of the cell. This transport protein shows sequence similarity with known efflux proteins that function to transport antibiotics such as chloramphenicol out of the cell. It has been shown that organisms which overexpress the transport protein become resistant to DHCP, probably because they are able to efficiently transport DHCP. Overexpression of the transport protein arises from the presence of multiple copies of the gene, rather than increased expression from the endogenous gene in *E. coli*. In other words, all *E. coli* possess a single copy of the transport gene. However, the level of transport protein expression from a single copy of the gene is insufficient to confer resistance to DHCP. The inventors have cloned the gene into a high copy number plasmid, pUC19, which is maintained in *E. coli* cells at 200-500 copies per cell. Thus, transformed *E. coli* containing this plasmid construct will possess 200-500 copies of the transport gene, and protein expression from multiple copies is greater than from a single copy. These transformed cells are resistant to DHCP.

The general mode of action of DHCP requires that it enter the target cell. Resistance to DHCP can occur if DHCP is transported out of the cell as fast as or faster than it enters the cell. Given that, the concentration of DHCP within the cell can never accumulate to a toxic dose and the cell is resistant to the antimicrobial effects of the compound. Apparently, the transport protein encoded by gene disclosed does not transport DHCP very efficiently, or the amount of transport protein expressed from the endogenous gene is very low. In either case, the presence of more transport protein (arising from many copies of the gene) will result in more efficient transfer of DHCP out of the cell.

Applications

An important application of the gene of the invention will be its use in studies to identify inhibitors of efflux activity. Such inhibitory compounds will function to block the transport activity. Thus a microbe or a tumor cell that is resistant to DHCP can be made to be more sensitive to the compound by preventing the resistant cell from transporting the compound back out. It is also conceivable that inhibitors of the transport gene of the invention may also be active in blocking transport of other efflux proteins such as the efflux proteins that transport chloramphenicol, or the P glycoprotein family of multiple drug resistant proteins. The P glycoproteins are expressed in many tumor cells, making these tumors resistant to chemotherapy agents. Abstracts regarding studies of P glycoproteins are referenced above.

DETAILED DESCRIPTION OF THE DRAWINGS

FIG. 1 is the chemical structure of 4,5-dihydroxy-2-cyclopenten-1-one (DHCP).

FIG. 2 Effect of DHCP concentrations on the growth of *E. coli*.

A. The JM83 cells were grown in LB medium up to Klett unit of 50 and DHCP was added at various concentrations (0-400 μ M). After the growth reached to Klett unit of 90-100, cells were diluted with medium containing respective concentrations of DHCP and growth was further monitored. DHCP concentration: 0 μ M, open squares; 50 μ M, closed diamonds; 100 μ M, open circles; 250 μ M, open diamonds; 400 μ M closed squares.

B. Overnight grown cells of *E. coli* JM83 were diluted appropriately and plated on LB plates containing different concentrations of DHCP (0-350 μ M). The number of colonies on the plate without DHCP was taken as 100% and the other numbers were expressed as relative percentages.

FIG. 3 Restriction mapping of the plasmid pSP001 conferring resistance to DHCP. Four ORFs comprising the DNA fragment (5.2 kb) conferring resistance to DHCP and the flanking ORFs are shown. The orientation of each ORF is marked with an arrow. The restriction enzyme sites are also shown. The ORFs are not drawn to scale. The plasmid pSP001 containing the DNA fragment conferring resistance to DHCP was digested with restriction enzymes to disrupt each of four ORFs, religated and transformed into JM83 cells. The transformants were then examined for their sensitivity to DHCP (400 μ M). The enzymes used for digestion were: for *purR*: *Mlu*I for *ydhB*; *Nru*I-*Eco*47III, for ORF389, *purR*, and *ydhB*: *Nru*I and *Sma*I, for ORF389: *Ava*I and for *purR* and *ydhB*: *Mlu*I and *Nru*I. For construction of plasmid with ORF389 (*dep*), the plasmid pSP001 was digested with *Sma*I and *Msc*I, the fragment was purified and cloned into pUC19 to yield plasmid pSP007.

FIG. 4 The sequence homology between Dep, Cmr, CmrA, Cmx, CmlV, BcR, Bmr3, YjcC and Tet. Identical and similar sequences are marked with black and gray boxes, respectively. The consensus sequences for transmembrane proteins are marked with dotted lines and are represented as I, II, and III stretches.

FIG. 5 Hydropathic profiles of Dep (A), Cmr from *Rhodococcus faciens* (B) (6) and Cml from *Streptomyces lividans* (C) (8). Horizontal bars indicate predicted transmembrane regions.

FIG. 6 is a nucleotide sequence showing the DNA sequence of a region of the *E. coli* genome containing the sequence of the *dep* gene. This region of the *E. coli* genome is available at Accession No. AE000261 U00096. The sequence shown is that of nucleotides 4381-8280. The *dep* gene is encoded by nucleotides 4627-5838. The *dep* sequence is shown in brackets.

FIG. 7 is a nucleotide sequence showing the isolated DNA sequence of the *dep* gene. The plasmid pSP007 was confirmed to contain the *dep* gene by obtaining DNA sequence data from one end of the 1.7 kb insert. Sequence data obtained in this manner matched the first.

Detailed Description of Experimental Work

Effect of DHCP on the growth of *E. coli*

The *E. coli* wild-type strain JM83 [*F*_{ara}Δ (*lac-proAB*) *rpsL*(*str*^r)] (Yanisch-Perron *et al.*, 1985) was grown in Luria broth (LB). Media were supplemented with ampicillin (final concentration of 50 µg/ml) whenever required. To check the effect of DHCP on the growth of *E. coli*, cells grown overnight in LB medium were diluted into fresh LB medium. After the growth reached to the Klett unit of 50, DHCP was added at various concentrations (0-400 µM) and growth was further monitored. After it reached to the Klett unit of 90-100, it was diluted 10-fold into media containing respective concentrations of DHCP. Fig. 2A shows the effect of different concentrations of DHCP on *E. coli*. The growth was slowed after 3 h of incubation in the presence of 50 µM DHCP, but it reached the maximum density after 8 h, similar to that without DHCP. The cells grew more slowly after 3 h incubation with 100 µM of DHCP and the maximum cell density was lower than that without DHCP. In the presence of 250 µM DHCP, growth was severely impaired after 3 h of incubation and cells stopped growing after 5 h. In the presence of 400 µM DHCP, cell growth stopped after 4 h of incubation. Microscopic examination of the cells grown with 250 µM DHCP for 8 h showed that the cells were elongated

forming filaments, which are approximately 15-fold longer than the control cells. DAPI (diamidino phenylindole)(Hiraga *et al.*, 1989) staining of these cells showed that the chromosomal condensation of the cells might be impaired by DHCP (data not shown).

To check the colony formation ability of *E. coli* at various concentrations of DHCP, cells grown overnight in LB medium were diluted appropriately and plated on LB plates containing DHCP (0-350 μ M). After incubation at 37 $^{\circ}$ C, the number of colonies on each plate were counted. The number of colonies on the control plate without DHCP was taken as 100% and the other numbers were expressed as relative percentages (Fig. 2B). In the presence of 300 μ M DHCP, 100-fold decrease in the colony numbers was observed. When 1×10^4 cells were plated on LB medium containing 350 μ M DHCP, no colonies were obtained.

Screening of an *E. coli* genomic library for genes conferring resistance to DHCP

In order to examine if *E. coli* contains a gene(s) that confers resistance to DHCP, the *E. coli* genomic library was screened. The construction of *E. coli* genomic library was described previously (Lu and Inouye, 1998). The partially digested *Sau*3AI chromosomal DNA fragments from *E. coli* JM83 were cloned into the *Bam*HI site of pUC19. The JM83 cells were transformed with the genomic library. Transformants were isolated for their ability to grow on DHCP (400 μ M) containing LB plates at 37 $^{\circ}$ C. Plasmid DNA was isolated from the resistant colonies, purified and retransformed into JM83 cells to confirm its ability to confer resistance to DHCP. The plasmid was designated as pSP001 and was found to contain a 5.2-kb DNA fragment. This fragment was sequenced from both ends using Sequenase and BLAST search was carried out for the analysis of homology of this fragment with the entire *E. coli* genome. It was found that this DNA fragment is located at 37.5 min on the *E. coli* chromosome and contains four ORFs (Fig. 3): ORF389, *purR* encoding purine synthesis repressor, *ydhB* encoding a homologue of the *cyn* operon transcriptional activator and *ydhC* encoding a homologue of bicyclomycin resistance protein (Berlyn *et al.*, 1996).

To determine which gene is responsible for conferring resistance to DHCP, several deletion constructs were prepared as shown in Fig. 3. Disruption of *purR*, *ydhB* and both *purR*

and *ydhB* had no effect on the resistance to DHCP (constructs pSP002, pSP003 and pSP006, respectively). However, disruption of ORF389 with *purR* and *ydhB* (pSP004) as well as disruption of ORF389 alone (pSP005) resulted in loss of DHCP resistance. We thus cloned ORF389 separately in pUC19 (pSP007), transformed the resultant plasmid in JM83 and checked sensitivity to DHCP. This plasmid conferred resistance to DHCP. These results clearly demonstrate that ORF389 is responsible for resistance to DHCP when cloned in a multicopy plasmid and further work was carried out using the plasmid pSP007. The ORF389 was named as *dep* – DHCP efflux protein (see below).

Homology analysis of ORF389 with other genes conferring drug resistance

Using BLAST-homology search computer program, we carried out a homology search for the putative protein encoded by *dep*. Fig. 4 shows nine proteins showing significantly high homology with Dep. Half of these proteins confer resistance to chloramphenicol. The proteins showing the highest degree of homology include: Cmr from *Rhodococcus fasciens* (Desomer *et al.*, 1992), CmrA from *R. erythropolis* (Nagy *et al.*, 1997), Cml from *Streptomyces lividans* 1326 (Dittrich *et al.*, 1991), Cmx from *Corynebacterium striatum* (Accession no. U72639), and CmlV from *S. venezuelae* ISP5230 (Mosher *et al.*, 1995). As seen from Fig. 4, Dep has the highest degree of homology with Cmr, product of chloramphenicol resistant gene (*cmr*) as compared to other proteins. Cmr protein was shown to contain three consensus sequences defined by Rouch *et al.* (1990) for transmembrane proteins. These sequences are at similar positions with respect to the predicted transmembrane domains. These are marked in Fig. 6 with dotted lines and are designated as I, II, III. In case of Dep, the first stretch (I) comprising of LP is completely homologous with the stretch defined by these authors. The second stretch (II) shows 50% similarity with that of Cmr protein and the third stretch (III) is homologous between these two proteins except for one residue. According to the model proposed by Rouch *et al.* (1990), the stretches I and III are located on the outside of the cytoplasmic membrane and the stretch II is located on the inside of the membrane. The positions of the membrane loops for the putative

protein encoded by *qacA* were ascertained by inspecting the antigenic index profile and turn prediction. Such regions have a high antigenic index and turn probability (Rouch *et al.*, 1990).

In addition to homology in the primary sequences, the hydropathic profile of Dep (Fig. 5A) is significantly similar to those of Cmr of *R. faciens* (Desomer *et al.*, 1992) (Fig. 5B) and Cml of *S. lividans* (Dittrich *et al.*, 1991) (Fig. 5C). Dep is predominantly hydrophobic and probably contains 12 predicted transmembrane α -helices (Fig. 5A).

The other proteins homologous to Dep include BcR (bicyclomycin- resistance protein) from *E. coli* (Bentley *et al.*, 1993), Bmr3 from *B. subtilis* involved in the multiple drug efflux pump conferring resistance to puromycin, tosufloracin, norfloxacin (Ohki and Murata, 1997), Tet from *Staphylococcus hyicus* conferring tetracycline resistance (Schwarz *et al.*, 1992) and YjcC conferring tetracenomycin-resistance (Accession no. D90826) (Fig. 4). All of these are efflux proteins, which is one of the most common mechanisms for drug resistance. We speculate that *dep* encodes a putative efflux protein that forms a cytoplasmic channel specific for DHCP. The homologies are more prominent towards the N-terminal end of the proteins, which also is a common feature for efflux proteins (Desomer *et al.*, 1992).

Measurement of minimum inhibitory concentrations for cells harboring pUC19 and pSP007

Since Dep shows homology to efflux proteins for multiple drug resistance, we checked if it confers resistance to other antibiotics as well. The *E. coli* wild-type cells harboring pUC19 or pSP007 plasmid were grown overnight in LB medium containing ampicillin. The cells were diluted 10- and 1000- times, and 5 μ l of each dilution (corresponding to 3.5×10^5 cells and 3.5×10^3 cells, respectively) was spotted on LB plates containing serial dilutions of kanamycin, chloramphenicol, spectinomycin, tetracycline and DHCP. Plates were incubated at 37 °C for 20 h. As seen from Table1, pSP007 did not confer significant cross-resistance to any of the antibiotics tested. The MIC values for cells harboring pUC19 and pSP007 were same for spectinomycin, chloramphenicol and tetracycline. The MIC value was two times higher for kanamycin for the cells harboring pSP007 than the cells with pUC19. The MIC value for DHCP

on the other hand was 8 times higher for the cells harboring pSP007 than that for the cells with pUC19. It is interesting that Dep did not confer resistance to chloramphenicol, in spite of the high homology to *cmr*.

5 **Table 1. Minimum inhibitory concentrations (MICs) of various antibiotics for *E. coli* JM83 cells harboring pUC19 and pSP007.**

	MICs ($\mu\text{g/ml}$)				
	kanamycin	spectinomycin	chloramphenicol	tetracycline	DHCP
cells with pUC19	25	12.5	6.25	3.125	25
cells with pSP007	50	12.5	6.25	3.125	200

MICs for both dilutions of the cells (3.5×10^5 and 3.5×10^3 cells) were the same.

In the Claims

We claim:

1. A DHCP efflux protein, which is specific for 4,5-dihydroxy-2-cyclopenten-1-one
5 (DHCP).
2. The protein of Claim 1, which is a transmembrane protein that forms a cytoplasmic channel specific for efflux transport of DHCP.
- 10 3. The protein of Claim 1, which confers resistance to DHCP.
4. The protein of Claim 1, which protein is from *E. coli*.
5. The protein of Claim 1, which protein does not confer cross-resistance to the any
15 of the following antibiotics: chloramphenicol, spectinomycin and tetracycline.
6. The protein of Claim 1, which protein possesses 13 predicted transmembrane-spanning α -helices.
- 20 7. A gene encoding *dep*, the DHCP efflux protein.
8. The *dep* gene of Claim 7, wherein the *dep* gene is from *E. coli*.
9. The gene of Claim 7, wherein said gene confers resistance to DHCP or a
25 functionally equivalent compound when present in multiple copies in a bacterial cell.

10. A plasmid comprising the *dep* gene, which plasmid confers expression of multiple copies of the *dep* gene in bacteria cells that have been transformed with said plasmid.

11. The plasmid of Claim 10, which plasmid confers resistance to DHCP and does not
5 confer cross-resistance to any of the following antibiotics: chloramphenicol, spectinomycin and tetracycline.

12. Bacteria cells containing multiple copies of the plasmid of Claim 10.

10 13. The bacteria cells of Claim 12, which bacteria cells are resistant to DHCP.

14. A method which uses the gene of Claim 7 to identify a compound which inhibits efflux activity responsible for resistance to DHCP or a functionally equivalent compound.




Fig. 1




Fig. 2




Fig. 3

II

I

Dep 1 ~~~~~
 Cmr 1 ~~~~~
 CmrA 1 ~~~~~
 Cml 1 ~~~~~
 Cmx 1 ~~~~~
 CmlV 1 ~~~~~
 Bcr 1 ~~~~~
 Bmr3 1 ~~~~~
 Yjcc 1 ~~~~~
 Tet 1 ~~~~~

III

Dep 84 ~~~~~
 Cmr 82 ~~~~~
 CmrA 82 ~~~~~
 Cml 82 ~~~~~
 Cmx 82 ~~~~~
 CmlV 106 ~~~~~
 Bcr 89 ~~~~~
 Bmr3 91 ~~~~~
 Yjcc 105 ~~~~~
 Tet 93 ~~~~~

Dep 189 ~~~~~
 Cmr 186 ~~~~~
 CmrA 186 ~~~~~
 Cml 189 ~~~~~
 Cmx 191 ~~~~~
 CmlV 214 ~~~~~
 Bcr 198 ~~~~~
 Bmr3 195 ~~~~~
 Yjcc 209 ~~~~~
 Tet 202 ~~~~~

Dep 282 ~~~~~
 Cmr 281 ~~~~~
 CmrA 281 ~~~~~
 Cml 284 ~~~~~
 Cmx 285 ~~~~~
 CmlV 306 ~~~~~
 Bcr 292 ~~~~~
 Bmr3 272 ~~~~~
 Yjcc 284 ~~~~~
 Tet 312 ~~~~~

Fig. 4

Fig 4 (cont.)

Dep	385	CVANS	~~~~~
Cmr	384	PALLVPP	~~~~~
CmrA	384	SQEVPA	~~~~~
Cml	386	APADATR	~~~~~
Cmx	388	APAN	~~~~~
CmlV	409	PGHVVARSGAGGTPSEPARGKATSSC	~~~~~
BcR	372	MTW...SIAPCATS..SILFCLYASRPKKR	~~~~~
Bmr3	354	...ARVW..LTVFMM..ISGFGVGFNFSL..P..AASMDLEPRFR..GTANSTNSFLRSFGMTLGVTFICGTVQTNVFTNKLNDAFSGMK.G..SAGSGA.AQNIGDPQE	~~~~~
YjcC	366	...HKKPI...IAVIMMALCG.G.GFGFFLS.PNORALMSS.APTTRSGAASGVLGISRILGQTTGATL...VAFCLYISSDHGAETALRIGIFIAFAGLYGQFVAFAE.	~~~~~
Tet	421	ENDSTYLSNLLLLFSGIIVISWLVTNLNLYKHSQDF	~~~~~
Dep	390	~~~~~	~~~~~
Cmr	392	~~~~~	~~~~~
CmrA	392	~~~~~	~~~~~
Cml	393	~~~~~	~~~~~
Cmx	392	~~~~~	~~~~~
CmlV	437	~~~~~	~~~~~
BcR	397	~~~~~	~~~~~
Bmr3	450	IFQAGTRSQIPDAIILNRIIDAMSSITY.VFLALIPIVLAAVTILEMGKARVKTTAEMTKKAN	~~~~~
YjcC	462	..KADFKKK.P..LLVRLYSRIKNVPSYLLF	~~~~~
Tet	459	~~~~~	~~~~~

Fig. 4 (cont.)




Fig. 5

4381 gccagccact ctccgctg adgcacggta tagctgacog cagaa ac gcatgacagc
4441 tccctgtgocg cagcgctaaa actaccatta cggcgctacog catcaaacac ttogagtga
4501 tattctgacc acatagtctg cctgcaaaat ttttgaaac agtcatcaaa tattaccgtt
4561 tcacaacact aatttcactc cctacacttt gggcggtgtt ttaattgaga gatttagaga
4621 atatacatgc aacctgggaa aagabtttta gtctggctgg cgggtttgag cgtactcgg
4681 tttctggcaa ccgatagtga tctgctgctt ttccgcca tacaggccga cctgcaaacg
4741 cctgcgtctg ctgtcagtgc cagccttagt ctgttccttg ccggttttgc cgcagccag
4801 cttctgtggg ggcgctctc cgaccgttat ggtcgtaaa cgggtattat aatcgccctg
4861 acaatttttg cgttaggtag tctggggtg ctgtgggtag azaacggccg tacgctgctg
4921 gtattgcgtt ttgtacagga tgtgggtgtc tgcgcggcgg cgggttatctg goaagcatta
4981 gtgacagatt attatccttc acagaaagtt aaccgtattt ttgoggccat catgocgctg
5041 gtgggtotat ctccggcact ggctcctctg ttagggaagc ggctgctggc ccatttttcc
5101 tggcaggoga ttttcgccac cctgttttgc attaccgtgg tgccgattct gcoatttttc
5161 tggctcaaac ccacgacgaa ggcccgtaac aatagtcagg atggtctgac ctttacggac
5221 ctgctacggt ctaaaacctc tcggggcaac gtgctgata acgcagccctg ttcagccag
5281 ttttttgcac ggttgacogg ttcaocgctt atccttagtg aaatgggcta cagccggca
5341 gttattgggt taagttaggt ccgcgcaact atcgcgtttc tgattgggtg ttatgggtgt
5401 cgcgcgcgcg tgcagaaatg gcaaggcaag cagttattac cgtgggtgtt ggtgctgtt
5461 gctgtcagcg tcattgcgac ctgggtctgc ggtttcatta gccatgtgtc gctgggtgaa
5521 atcctgatcc cattctgtgt gatggcgatt gccaatggcg cgtctaccc tatgtgtct
5581 gccacggcgc tgcgtccctt cccacacgca actgggtcgc ccgcagcgtt gcagaacact
5641 cttcaactgg gtctgtgctt cotcgcaagt ctggtagttt cctggctgat cagtatcagc
5701 acgcaattgc tcaccacac cagcgtgatg ttaaccaag taatgctggc cgcgctgggt
5761 tacatgatgc aacgttgtga agaagttggc tgcagaaatc atggcaatgc cgaagtgcct
5821 catagcgaat cacactgac tatatcgata tacttatact taggctgcta acaaaatttt
5881 gttgtatgat tgaatttagc ggcctatact aatttcagat tgttaaagot acgataaata
5941 ttatgttttt acggggacag gatcgttccc gactcactat ggtagtcat ttccggcaagg
6001 gttcctcctt tcctctgtt ctaogtcgga ttatagactc gcggtttttt ctgcagatt
6061 tctdcaaaag cccaaaaagc gtctacgctt ttttaagggt ctgctcaccc accagtgatg
6121 gagaaactat gatttcctog tgtatagaag aagtcagtgt accggatgac aactgggtacc
6181 gtatogccaa cgaattactt agcogtgcgc gtatagccat taacgggtct gccccggcgc
6241 atattcgtgt gaaaaacccc gattttttta aacgggtctt gcaagaagge tctttgggggt
6301 taggcgaagc ttatatggat ggtggtggg aatgtgaccc actggatatt ttttttagca
6361 aagtcttacg cgcaggtctc gagaaccaac tccccatca cttcaaaag acgctcgta
6421 ttgcgggcgc tctctctctt aatctgcaga gtaaaaaacg tgcctggata gtcggcaag
6481 agcattacga tttgggtaat gacttgctta gccgatgct tgatcccttc atgcaatatt
6541 cctgogctta ctgaaagat ggcgataatc tggaaatctg ccagcaggcg aagctcaaaa
6601 tgattttgtg aaaaattgcag ttaaaaccag ggatggcgtt actggatatt ggctgcggct
6661 ggggcggact ggcacactac attatgacgt aagcgtgggt aagcgtggat gtcacattt
6721 tttctgcga acagcaaaaa atcgctcagg aacgctgtga aggcctggat gtcacattt
6781 tgcgtcaaga ttatogtgac ctgaaacgac agttttgatc tattgtttct gtcggggtgt
6841 tcgagcaagt cggacggaaa aattacgata cctattttgc ggtggtggat cgtaatctga
6901 aacgggaagg catattcctg ctccatacta tcgggttogaa aaaaacogat ctgaaatgtt
6961 atccctggat taabaaatat atttttccga aoggttgcct gccctctgta cgcagattg
7021 ctcagtccag cgaacccac tttgtgatgg tttgtgatgg taactcgggt gctgattacg
7081 ataactagtt gatggcgtgg tatgaacgat tctcgcgcgc atggccagaa attgcccgata
7141 actatagtga acgctttaaa cgaatgttta cctattatct gaatgcctgt goaggtgctt
7201 tcgcgcgcgc tgatattcag ctctggcagg togtgttctc aogcgggtgt gaaaacggcc
7261 ttcgagtggtc tcgctaaagg ctattctatc gccccctctc cgggggogat ttcagatcag
7321 gcttctgttc ctggttgatt catggcattt totcgtgccc ccagcacag ttoaacgta
7381 tctaccactg cctgagtttg tggatcgatt toaatgttga cgcgtgcgc aagtttttcc
7441 tccccaagag tcgtgogtto cagtgttttc ggaattaaat ggaocgcaaaa acgcttggc
7501 gtgacttcgc cgcggctcag gctaatacog tcgatgcocaa taaatccttt ggcagataa
7561 tatttcacac actgactatc ctggaactta aaccagatct ggcatattt ttctgaggt
7621 aatatttttc ccacttcagc agtggctata atabgacotg acattaaagt tccgcgaat
7681 tcatcaactga atttcgcgc acgctcaacg ttttaaccaat ccccaacttt taaatcgca
7741 agattggtaa tgcgtaacgt ttctttcatc aggtcaaaac tgacatgggt googtbaatt
7801 tccgtcacgg tcaggcagca accgttatgc gccacgggaag caccoggttc cagggcgtcc
7861 agcatgtggt cgggtaaact caccacatgc gtaacgaaaat ttggtttctc gtcacacgac
7921 accagttttg cgggtgcctg tacaatcccc gtaaacatac ttaaacactc tgaaatcagt
7981 taagacattc tgttcagcac aatagcaggt ggaacacgoc cttaccagtc aaggggtaag
8041 aatggctatt ttttcactgg agaatttaata aatcctcgct gaatttcccc
8101 tgcctctctt ccttgctgac cattcaggcg gctttttagt ctctcatata actacaaata
8161 aaaggtgttc acgtgcagaa gtatatcagt gaagcgcgtc tggtatttagc attagcaatc
8221 ccggtgattc tcgcgcaaat cgcaccaact gogattgggtt ttgtcagtae cgtgatggcg

FIG. 6

4681 [atgc aacctgggaa aagattttta gtctggctgg cgggtttgag cgtactcggc
4741 cctgcgtctg ccgatatgta tctgcctgct ttgcgcgcga tacaggccga] cctgcaaacg
4801 cttctgtggg ggcgcgtctc cagccttagt ctgttctctg ccggttttgc cgcagcccag
4861 acaatttttg cgttaggtag tctggggatg ctgtgggtag aaaacgcgcg tacgctgctg
4921 gtattgcgtt ttgtacaggc tgtgggtgtc tgcgcgcggg cggttatctg gcaagcatta
4981 gtgacagatt attatocctc acagaaagt aaacgtattt ttgaggccat gatgcgcgtg
5041 gtgggtctat ctccggcact ggctcctctg ttaggaagct ggctgctggc ccatttttcc
5101 tggcaggcga ttttcgcac ccacgacgaa ggcccgtaac aatagtcagg atggctctgac ctttacccac
5161 tgggtcaaac ccacgacgaa tgcgggcaac gtgctgatat aagcagccctg ttcagccagt
5221 ctgctaogtt ctaaaaacct ttcaacgttc atccttagtg aaatgggcta cagcccgga
5281 ttttttgcac ggctgacggg ccgcgaaact atgcgcttcc tgattgggtg ttatggctgt
5341 gttattgggt tgcagaaatg tcaaggcaag cagttattac cgtggttgct ggtgctgttt
5401 cgcgcgcgcg tcatgtcgac ctgggctgct ggcttcatta gccatgtgtc gctggctgaa
5461 gctgtcagcg cattctgtgt gatggcgatt gccaatggcg cgatctaccc tattgttgtc
5521 atcctgatcc tgcgtccctt cccacacgca actggctcgc ccgcagcgtt gcagaacact
5581 gccoaggcgc gtctgtgctt cctcgcaagt ctggtagttt cctggctgat cagtatcagc
5641 cttcaactgg tcacccaccac cagcgtgatg ttatcaacag taatgctggc cgcgctgggt
5701 acgcaattgc aacgttgtga agaagttggc tgcagaaatc atggcaatgc cgaagtcgct
5761 tacatgatgc
5821 catagcgaat cacactga

FIG. 1

SEQUENCE LISTING

<110> INOUE, MASAYORI
PHADTARE, SANGITA
YAMANAKA, KUNITOSHI
KATO, IKUNOSHIN

<120> ANTIBACTERIAL ACTIVITY OF 4.5 DIHYDROXY-2-CYCLOPENTAN-1-ONE
(DHCP) AND CLONING A GENE CONFERRING DHCP RESISTANCE IN
ESCHERICHIA COLI

<130> 1137-P-00

<140>

<141>

<150> 60/228,727

<151> 2000-08-29

<160> 2

<170> PatentIn Ver. 2.1

<210> 1

<211> 3900

<212> DNA

<213> Escherichia coli

<400> 1

```
gccagccact cttccagctg acgcacggta tagctgaccg cagaaggaac gcgatgcagc 60
tcctgtgccc cagcgctaaa actaccatta cgcgctaccg catcaacaac ttcgagtga 120
tattctgacc acatagtctg cctgcaaaaat ttttgaaacc agtcatcaaa tattaccgtt 180
tcacaacact aatttcactc cctacacttt gcggcggtgt ttaattgaga gatttagaga 240
atatacatgc aacctgggaa aagattttta gtctggctgg cgggtttgag cgtactcgg 300
tttctggcaa ccgatatgta tctgcctgct ttgcgcgcca tacaggccga cctgcaaacc 360
cctgcgtctg ctgtcagtcg cagccttagt ctgttccttg ccggttttgc cgcagcccag 420
cttctgtggg ggccgctctc cgaccgttat ggctgtaaac cgggtattatt aatcggcctg 480
acaatttttg cgttaggtag tctggggatg ctgtgggtag aaaacgccgc tacgctgctg 540
gtattgcgtt ttgtacaggc tgtgggtgtc tgcgcgcggc cggttatctg gcaagcatta 600
gtgacagatt attatccttc acagaaagtt aaccgtattt ttgcggccat catgccgctg 660
gtgggtctat ctccggcact ggctcctctg ttaggaagct ggctgctggg ccatttttcc 720
tggcaggcga ttttcgccac cctgtttgcc attaccgtgg tgetgattct gcctattttc 780
tggctcaaac ccacgacgaa ggcccgtaac aatagtcagg atggtctgac ctttaccgac 840
ctgctacggt ctaaaacctc tcgcggcaac gtgctgatat acgcagcctg ttcagccagt 900
ttttttgcat ggctgaccgg ttcaccgttc atccttagtg aaatgggcta cagcccggca 960
gttattgggt taagtattgt cccgcaaaact atcgcgtttc tgattgggtg ttatggctgt 1020
cgcgcgcgcg tgcagaaatg gcaaggcaag cagttattac cgtgggttgc ggtgctgttt 1080
gctgtcagcg tcattgcgac ctgggctgcg ggcttcatta gccatgtgtc gctggtcgaa 1140
atcctgatcc cattctgtgt gatggcgatt gccaatggcg cgatctaccc tattgttgtc 1200
gcccaggcgc tgcgtccctt cccacacgca actggctgcg ccgcagcgtt gcagaacact 1260
cttcaactgg gtctgtgctt cctcgcaagt ctggtagttt cctggctgat cagtatcagc 1320
acgccattgc tcaccaccac cagcgtgatg ttatcaacag taatgctggg cgcgctgggt 1380
tacatgatgc aacgttgtga agaagtggc tgccagaatc atggcaatgc cgaagtgcgt 1440
catagcgaat cacactgacc tatatcgata tacttatact taggctgcta acaaaat 1500
gttgtatgat tgaaattagc ggctatact aatttcgagt tgttaaagct acgataaata 1560
ttatgttttt acggggacag gatcggtccc gactcactat ggatagtcac ttcggcaagg 1620
gttcctcctt tccctctgtt ctacgtcgga ttatagactc gcggtttttt ctgcgagatt 1680
tctcaciaag cccaaaaagc gtctacgctg ttttaagggt ctgatcaccg accagtgatg 1740
```

```

gagaaactat gagttcatcg tgtatagaag aagtcagtggt accggatgac aactgggtacc 1800
gtatcgccaa cgaattactt agccgtgcgc gtatagccat taacgggttct gccccggcgg 1860
atattcgtgt gaaaaacccc gattttttta aacgcgttct gcaagaaggc tctttgggggt 1920
taggcgaaag ttatatggat ggctgggtggg aatgtgaccg actggatatg ttttttagca 1980
aagtcctacg cgcaggctctc gagaaccaac tccccatca tttcaaagac acgctgcgta 2040
ttgcgggcgc tcgtctcttc aatctgcaga gtaaaaaacg tgccctggata gtcggcaaaag 2100
agcattacga tttgggtaat gacttggtca gccgcgtgct tgatcccttc atgcaatatt 2160
cctgcgctta ctggaaagat gccgataatc tggaaatctgc ccagcaggcg aagctcaaaa 2220
tgatttgtga aaaattgcag ttaaaaccag ggatgcgcgt actggatatt ggctgcggct 2280
ggggcgggact ggcacactac atggcatcta attatgacgt aagcgtgggtg ggcgtcacca 2340
tttctgcoga acagcaaaaa atggctcagg aacgctgtga aggcctggat gtcaccattt 2400
tgctgcaaga ttatcgtgac ctgaacgacc agtttgatcg tattgtttct gtggggatgt 2460
tcgagcacgt cggaccgaaa aattacgata cctattttgc ggtggtggat cgtaatattga 2520
aaccggaagg catattcctg ctccatacta tcggttcgaa aaaaaccgat ctgaatgttg 2580
atccctggat taataaatat atttttccga acggttgccct gccctctgta cgccagattg 2640
ctcagtcacg cgaaccccac tttgtgatgg aagactggca taacttcggg gctgattacg 2700
atactacgtt gatggcgtgg tatgaacgat tcctcgccgc atggccagaa attgcggata 2760
actactgtga acgcttttaa cgaatgttta cctattatct gaatgcctgt gcagggtgctt 2820
tcgcgcgcgc tgattttcag ctctggcagg tcgtgttctc acgcgggtgtt gaaaacggcc 2880
ttcgagtggc tcgctaaagg ctattctatc gccctctctc cgggggcgat ttcagatcag 2940
gcttctgtgc ctggttgatt catggcattt tctcgtgccg ccagcacacg ttctaccgta 3000
tctaccactg cctgagtttg tggatcgatt tcaatgttga cgcgtgcgc aagtttttct 3060
ttcccaagag tcgtgcgttc cagtgtttcc ggaattaaat ggacgcaaaa acgcgttggtc 3120
gtgacttcgc cgacggtcag gctaataccg tcgatgccaa taaatccttt gtacagaata 3180
tatttcatca actgactatc ctggacttta aaccagatct ggcgattatt ttctgaggtt 3240
aatattttcg ccacttcagc agtggtcata atatgacctg acattaagtg tccgccaat 3300
tcatcactga atttcgcgc acgctcaacg tttacccaat cccccaactt taaatcgcca 3360
agattggtaa tgcgtaacgt ttctttcatc aggtcaaaac tgacatgggt gccgttaatt 3420
tcggtcacgg tcaggcagca accgttatgc gccacggaag caccggtttc caggccgtcc 3480
agcatgtggt cgggtaactc caccacatgc gtacgaaaat ttggtttctc gtcaatcgac 3540
accagttttg cggtcgctg tacaatcccc gtaaacatac ttacaactcc tgaaatcagt 3600
taagacattc gtctcagcac aatagcaggt ggaaaacgcc cttaccagt aaggggtaag 3660
aatggctatt ttttcaactg agaattaata aatcctcgct acaatagact gaatttcccc 3720
tgcttcttct ttttgcgtgc cattcaggcg gcttttttagt ctctcatata actacaaata 3780
aaaggtgttc acgtgcagaa gtatatcagt gaagcgcgtc tgttatttagc attagcaatc 3840
ccggtgatcc tcgcgcaaat cgcccaaact gcgatgggtt ttgtcagtag cgtgatggcg 3900

```

<210> 2

<211> 1212

<212> DNA

<213> Escherichia coli

<400> 2

```

atgcaacctg ggaaaagatt tttagtctgg ctggcggggt tgagcgtact cggttttctg 60
gcaaccgata tgtatctgcc tgctttcgcc gccatacagg ccgacctgca aacgcctgcg 120
tctgctgtca gtgccagcct tagtctgttc cttgccgggt ttgccgcagc ccagcttctg 180
tgggggccgc tctccgaccg ttatggctcg aaaccggtat tattaatcgg cctgacaatt 240
tttgcgttag gtagtctggg gatgctgtgg gtagaaaacg ccgtacgct gctgggtattg 300
cgttttgtac aggctgtggg tgtctgcgcc gcggcgggta tctggcaagc attagtgaca 360
gattattatc cttcacagaa agttaaccgt atttttgcgg ccacatgcc gctgggtgggt 420
ctatctccgg cactggtccc tctgttagga agctggctgc tgggtccattt ttccctggcag 480
gogattttcg ccacctgtt tgccattacc gtgggtgctga ttctgcctat tttctggctc 540
aaaccacga cgaaggcccg taacaatagt caggatgggtc tgacctttac cgacctgcta 600
cgttctaaaa cctatcgcgg caacgtgctg atatacgcag cctgttcagc cagttttttt 660
gcatggctga ccggttcacc gttcatcctt agtgaaatgg gctacagccc ggcagttatt 720
ggtttaagtt atgtcccga aactatcgcg tttctgattg gtggttatgg ctgtcgcgcc 780
gcgctgcaga aatggcaagg caagcagtta ttaccgtggt tgctggtgct gtttgcgtgc 840

```

```
agcgtcattg cgacctgggc tgcggggcttc attagccatg tgcgcgtggt cgaaatcctg 900
atcccattct gtgtgatggc gattgccaat ggcgcgatct accctattgt tgcgcccag 960
gcgctgcgtc ccttcccaca cgcaactggt cgcgcgcgag cgttgagaa cactcttcaa 1020
ctgggtctgt gcttcctcgc aagtctggta gtttcctggc tgatcagtat cagcacgcca 1080
ttgctacca ccaccagcgt gatgttatca acagtaatgc tggcgcgcgt gggttacatg 1140
atgcaacgtt gtgaagaagt tggctgccag aatcatggca atgccgaagt cgctcatagc 1200
gaatcacact ga 1212
```

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/26961

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/12

US CL : 530/350; 536/23.1; 435/6

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350; 536/23.1; 435/6

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN: MEDLINE, BIOSIS, WPIDS, JAPIO, USPAT, EMBASE, DGENE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	Database HCAPLUS on STN (Piscataway, NJ, USA), No.135:119459, 'Antibacterial Activity of 4, 5-dihydroxy-2-cyclopenten-1-one (DHCP) and Cloning of a Gene Conferring DHCCP Resistance in Escherichia coli, Journal of Molecular Microbiology Biotechnology', abstract, Phadtare et al., 2001.	1-14
A	US 6,087,401 A (KOYAMA ET AL) 11 July 2000 (11/7/00), see entire document.	1-14
A	US 6,228,892 B1 (TOMINAGA ET AL) 08 May 2001 (08/05/01), see entire document.	1-14
A	WO 99/36383 A1 (TAKARA SHUZO CO., LTD), 22 JULY 1999 (22/07/99), see entire document.	1-14



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"G" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

24 OCTOBER 2001

Date of mailing of the international search report

17 DEC 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

HOPE ROBINSON

Telephone No. (703) 308-0196